Alison Turner

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers

Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea et al. · Cancer Discovery · 2020 · 130 citations · Full text

Plasma Creatinine Rises Dramatically in the First 48 Hours of Life in Preterm Infants

Lawrence Miall, Michael Henderson, Alison Turner et al. · PEDIATRICS · 1999 · 113 citations

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Christina Guo, Adam Sharp, Bora Gürel et al. · Nature · 2023 · 103 citations · Full text

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Christina Guo, Maxime Chénard-Poirier, Desamparados Roda et al. · The Lancet Oncology · 2020 · 68 citations

Hematological Malignancy, Medicine, Pharmacology +10

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal et al. · Journal for ImmunoTherapy of Cancer · 2022 · 47 citations · Full text